Drug news
Nuedexta is filed at EU for Pseudobulbar Affect
Avanir Pharmaceuticals has submitted an EU marketing authorisation application for Nuedexta (dextromethorphan HBr and quinidine sulfate) for the treatment of Pseudobulbar Affect(PBA). PBA is a neurological disorder, secondary to neurological disease or brain injury (e.g. Parkinsons, Alzheimers or Multiple Sclerosis) causing unpredictable episodes of crying, laughing and other emotional displays out of proportion to the underlying emotional state. Nuedexta was approved in the USA in October 2010 and has earned some $4 million in sales.
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.
1 mins